このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Mirogabalin vs. Melatonin for Pain and Anxiety After Total Knee Arthroplasty Under Spinal Anesthesia

2026年11月18日 更新者:Kerollos Moneer Neseem Mikhael、Beni-Suef University

Mirogabalin Versus Melatonin for Perioperative Anxiolysis and Opioid-Sparing Analgesia After Total Knee Arthroplasty Under Spinal Anesthesia: A Double-Blind, Randomized, Placebo-Controlled Trial

Total knee arthroplasty (TKA) is frequently associated with moderate-to-severe postoperative pain, substantial opioid consumption, and preoperative anxiety. Although spinal anesthesia is preferred for TKA, it does not provide prolonged analgesia after the block resolves.

This prospective, randomized, double-blind, placebo-controlled trial aims to evaluate and compare the efficacy of perioperative oral mirogabalin versus melatonin versus placebo as opioid-sparing analgesic adjuncts in patients undergoing elective unilateral TKA under spinal anesthesia. The primary objective is to assess their impact on postoperative pain intensity and perioperative anxiety levels.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

Preoperative anxiety affects 30% to 70% of patients undergoing total knee arthroplasty (TKA) and can exacerbate postoperative pain, increase opioid consumption, and delay recovery. Multimodal perioperative optimization within Enhanced Recovery After Surgery (ERAS) protocols is essential to address these challenges.

Mirogabalin is a novel, selective ligand of the α₂δ subunit of voltage-gated calcium channels with a long dissociation half-life, demonstrating analgesic and anxiolytic properties. Melatonin is an endogenous pineal hormone with well-characterized chronobiotic, sedative, anxiolytic, and antinociceptive actions. Despite their potential, no randomized controlled trial has directly compared mirogabalin and melatonin for perioperative optimization in TKA under spinal anesthesia.

Eligible consenting participants (aged 50-70 years, ASA I-III, scheduled for primary elective unilateral TKA under spinal anesthesia) will be randomized (1:1:1) to one of three parallel groups:

  1. Mirogabalin Group: Oral mirogabalin administered at 10:00 PM the night before surgery, 1 hour before spinal anesthesia, 10:00 PM on surgery day, and at 10:00 AM and 10:00 PM on Postoperative Day 1.
  2. Melatonin Group: Oral melatonin administered at 10:00 PM the night before surgery, 1 hour before spinal anesthesia, and 10:00 PM on surgery day; matching placebo at 10:00 AM on Postoperative Day 1, followed by melatonin at 10:00 PM on Postoperative Day 1.
  3. Placebo Group: Matching placebo administered at identical time points.

All patients will receive standardized intraoperative spinal anesthesia (hyperbaric bupivacaine + fentanyl) and standardized background multimodal analgesia (paracetamol, ketorolac, and intraoperative dexamethasone).

Outcomes assessed up to 48 hours postoperatively include Numeric Rating Scale (NRS) pain scores, Amsterdam Preoperative Anxiety and Information Scale (APAIS) scores, 24-hour and 48-hour cumulative opioid (nalbuphine) consumption, time to first rescue analgesia, sedation level (MOOA/S), sleep quality (SQS), time to first mobilization, hemodynamic stability, and adverse events.

研究の種類

介入

入学 (推定)

78

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Kerollos Moneer Neseem Mikhael, MD
  • 電話番号:00201288549959
  • メール:Kmnmk87@med.bsu.edu.eg

研究場所

      • Banī Suwayf、エジプト
        • Beni-Suef University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

50年~70年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age 50 to 70 years.
  • American Society of Anesthesiologists (ASA) physical status I, II, or III.
  • Scheduled for elective primary unilateral total knee arthroplasty (TKA) under spinal anesthesia.
  • Body Mass Index (BMI) between 18.5 and 35 kg/m².
  • Able to understand and complete study questionnaires (APAIS, NRS) in the local language.
  • Provision of signed written informed consent.

Exclusion Criteria:

  • Contraindication to spinal anesthesia (e.g., coagulopathy, local puncture site infection, severe spinal deformity, or patient refusal).
  • Known hypersensitivity or allergy to mirogabalin, melatonin, gabapentinoids, or study medication excipients.
  • Pre-existing chronic pain syndrome requiring long-term opioid, gabapentinoid, or melatonin therapy.
  • Severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m²) or end-stage renal disease.
  • Severe hepatic impairment (Child-Pugh class C).
  • Psychiatric illness impairing comprehension or cooperation (e.g., dementia, active psychosis) or current treatment with anxiolytics, antipsychotics, or antidepressants.
  • Current pregnancy or breastfeeding.
  • Revision arthroplasty, bilateral TKA procedures, or intraoperative conversion to general anesthesia.
  • Known sleep disorder under active pharmacological treatment, or current shift-work disorder.
  • Participation in another interventional drug trial within 30 days prior to enrollment.
  • Inability to complete visual/numeric pain and anxiety scales due to visual, cognitive, or language barriers.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group G (Mirogabalin)

Patients receive oral mirogabalin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on the first postoperative day (Postoperative Day 1). All participants receive standardized spinal anesthesia (hyperbaric bupivacaine 0.5% + fentanyl 25 mcg) and multimodal background analgesia (paracetamol 1 g IV q6h, ketorolac 30 mg IV q12h, and intraoperative dexamethasone 8 mg IV).

Oral mirogabalin 10 mg tablet administered per protocol schedule (5 total doses perioperatively).

アクティブコンパレータ:Group M (Melatonin)

Patients receive oral melatonin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, and 10:00 PM on the day of surgery. On Postoperative Day 1, patients receive a matching placebo tablet at 10:00 AM (to preserve blinding), followed by melatonin 10 mg at 10:00 PM. All participants receive standardized spinal anesthesia and identical background multimodal analgesia.

Oral melatonin 10 mg tablet administered per protocol schedule (4 active doses + 1 placebo dose at 10:00 AM POD 1).

プラセボコンパレーター:Group P (Placebo)

Patients receive matching oral placebo tablets administered at corresponding time points: 10:00 PM the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on Postoperative Day 1. All participants receive standardized spinal anesthesia and identical background multimodal analgesia.

Matching inert oral placebo tablet administered to Group P (5 total doses) and Group M (1 dose at 10:00 AM POD 1).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Postoperative Pain Intensity Scores
時間枠:Assessed at 2, 12, 24, and 48 hours postoperatively.

Assessed using the Numeric Rating Scale (NRS), where scores range from 0 to 10 (0 = "no pain", 10 = "worst possible pain"). Lower scores represent a more favorable clinical outcome (less pain intensity), whereas higher scores represent an unfavorable outcome.

Assessed at 2, 12, 24, and 48 hours postoperatively.
Perioperative Anxiety Scores
時間枠:Preoperatively (holding area, 60-120 minutes before spinal anesthesia), and postoperatively at 2 and 12 hours.

Assessed using the anxiety subscale of the Amsterdam Preoperative Anxiety and Information Scale (APAIS). The anxiety subscale consists of 4 items rated on a 5-point Likert scale (1 = not at all, 5 = extremely), with total anxiety scores ranging from 4 to 20. Lower scores represent a more favorable clinical outcome (lower anxiety), whereas higher scores represent an unfavorable outcome.

Preoperatively (holding area, 60-120 minutes before spinal anesthesia), and postoperatively at 2 and 12 hours.

二次結果の測定

結果測定
メジャーの説明
時間枠
Total Cumulative Postoperative Opioid Consumption
時間枠:First 24 and 48 hours postoperatively.

Total intravenous nalbuphine consumption measured in milligrams (mg) administered as rescue analgesia during the first 24 and 48 postoperative hours. Lower cumulative dose values represent a more favorable outcome (greater opioid-sparing effect).

First 24 and 48 hours postoperatively.
Time to First Request for Rescue Analgesia
時間枠:Up to 48 hours postoperatively.

Time elapsed (in minutes) from arrival in the Post-Anesthesia Care Unit (PACU, time zero) to the first administration of rescue IV nalbuphine for NRS pain score >= 4. Longer duration (higher values in minutes) represents a more favorable outcome (prolonged postoperative analgesia).

Up to 48 hours postoperatively.
Postoperative Sedation Scores
時間枠:Assessed at 2, 12, 24, and 48 hours postoperatively.

Evaluated using the Modified Observer's Assessment of Alertness/Sedation (MOOA/S) scale, ranging from 0 (does not respond to deep algic stimulus) to 5 (responds readily to name spoken in normal tone). A score of 5 represents alertness (favorable recovery state), whereas lower scores indicate deeper sedation (unfavorable/excessive drug-induced sedation).

Assessed at 2, 12, 24, and 48 hours postoperatively.
Incidence of Postoperative Nausea and Vomiting and Requirement for Rescue Antiemetics
時間枠:Assessed at 2, 12, 24, and 48 hours postoperatively.

Number of participants experiencing nausea or vomiting and requiring rescue antiemetic therapy. A lower incidence (fewer participants affected) represents a favorable outcome.

Assessed at 2, 12, 24, and 48 hours postoperatively.
Postoperative Sleep Quality Score
時間枠:Assessed at 48 hours postoperatively.

Assessed using the Single-Item Sleep Quality Scale (SQS), where overall sleep quality over the 48-hour postoperative period is rated on a 0 to 10 scale (0 = terrible, 10 = excellent). Higher scores represent a more favorable outcome (better sleep quality).

Assessed at 48 hours postoperatively.
Time to First Postoperative Mobilization
時間枠:Up to 48 hours postoperatively.

Time elapsed (in hours) from arrival in the PACU to first achieving bedside sitting and subsequent assisted ambulation. Shorter duration (lower values in hours) represents a more favorable recovery outcome.

Up to 48 hours postoperatively.
Incidence of Treatment-Emergent Adverse Events
時間枠:Up to 48 hours postoperatively.

Number of participants experiencing adverse drug events, including dizziness, excessive somnolence, headache, pruritus, constipation, and urinary retention. A lower incidence represents a more favorable safety profile.

Up to 48 hours postoperatively.
Incidence of Intraoperative Hypotension and Bradycardia
時間枠:Intraoperatively (from spinal injection to completion of surgery).

Number of participants experiencing spinal-anesthesia-related hypotension (mean arterial pressure drop > 20% from baseline requiring IV fluids/ephedrine) or bradycardia (heart rate < 50 bpm requiring IV atropine). A lower incidence represents a more favorable hemodynamic stability profile.

Intraoperatively (from spinal injection to completion of surgery).
Patient Satisfaction With Perioperative Analgesia
時間枠:Assessed at 24 hours postoperatively.

Evaluated on a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied). Higher scores represent a more favorable outcome.

Assessed at 24 hours postoperatively.
Length of Postoperative Hospital Stay
時間枠:From completion of surgery (arrival in the PACU) until the date and time of meeting formal hospital discharge criteria, assessed up to 7 days postoperatively.

Duration of hospital stay measured in hours from completion of surgery until meeting formal discharge criteria. Shorter stay duration (lower values) represents a more favorable outcome.

From completion of surgery (arrival in the PACU) until the date and time of meeting formal hospital discharge criteria, assessed up to 7 days postoperatively.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2027年5月1日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2026年11月15日

QC基準を満たした最初の提出物

2026年11月18日

最初の投稿 (実際)

2026年11月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月18日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • FMBSUREC/03112026/Mahmoud

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data (IPD) underlying the published results (including baseline demographics, intervention group allocation, pain scores, anxiety scores, cumulative opioid consumption, and adverse event data) will be made available to qualified researchers upon reasonable request to the

IPD 共有時間枠

Beginning 6 months and ending 3 years following article publication

IPD 共有アクセス基準

Available to academic researchers who provide a methodologically sound proposal approved by the Beni-Suef University Research Ethics Committee

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。